Greater China News
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion.
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform
GSK enters exclusive license agreement with Hansoh for HS-20093
HS-20093 is currently being investigated in ongoing phase I and II trials in China.
“Windtree and Lee’s sign licence deal for heart failure therapy”
Windtree is entitled to receive $138.1m in milestone payments.
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.
GSK enters agreement to acquire Aiolos Bio
AIO-001 has potential to expand GSK’s respiratory biologics portfolio to reach a broader portion of asthma patients
Pfizer and Astellas’ XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI
